

# Studierna som förändrat mitt kliniska arbete

Bertil Ekman  
Endodiabetes Linköping  
2025-03-28

# Första läkarstämman 1992


Chou YH, Brown EM, Levi T, Crowe G, Atkinson AB, Arnqvist HJ, Toss G, Fuleihan GE, Seidman JG, Seidman CE.

The gene responsible for familial hypocalciuric hypercalcemia maps to chromosome 3q in four unrelated families. *Nat Genet.* 1992 Jul;1(4):295-300.

Winqvist O, Karlsson FA, Kämpe O.


21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. *Lancet.* 1992 Jun 27;339(8809):1559-62.

# GH substitution



Ekman B, Lindström T, Nyström F, Olsson AG, Toss G, Arnqvist HJ. A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults. *Eur J Endocrinol.* 2002 Jul;147(1):49-57.

# IGF-I vuxen ålder




**Fig 3.** IGF-I in relation to age

Nyström FH, Ohman PK, Ekman BA, Osterlund MK, Karlberg BE, Arnqvist HJ.  
Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur J Endocrinol. 1997 Feb;136(2):165-72.

# Macimorelin: Dosage and administration<sup>1</sup>

The use of Macimorelin Consilient Health must be supervised by a physician or healthcare professional experienced in diagnosing growth hormone deficiency

Weigh your patient\*



≤120 kg=1 sachet  
>120 kg=2 sachets

Dissolve in water




1 sachet=120 ml water  
2 sachets=240 ml water

Stir gently  
(for 2-3 minutes)



(a small amount of undissolved particles will remain)

Calculate volume



Example: A patient weighing 70 kg will need 70 ml of reconstituted macimorelin solution

Measure exact volume



Use a syringe with graduations in ml to measure the exact volume of solution

Transfer exact volume



Transfer the exact required volume of macimorelin solution into drinking glass

Administer solution



Patient drink the entire volume of macimorelin solution in drinking glass within 30s

Draw blood samples



Draw venous blood samples for GH determination at 45, 60, and 90 minutes

\* Patients must be fasted for at least 8 hours.


1. Macimorelin, 60mg Sachets Summary of Product Characteristics Consilient Health Ltd.

Cut off  
GH <2,8 ug/L (5,1)

Garcia JM, Biller BMK, Korbonits M, Popovic V, Luger A, Strasburger CJ, Chanson P, Medic-Stojanoska M, Schopohl J, Zakrzewska A, Pekic S, Bolanowski M, Swerdloff R, Wang C, Blevins T, Marcelli M, Ammer N, Sachse R, Yuen KCJ. Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab. 2018 Aug 1;103(8):3083-3093.

### Maintenance dose of GH


The median GH dose was significantly affected by gender, males 0.33 mg/day (0.17-1.17) vs. females 0.83 mg/day (0.33-1.33) ( $P=0.017$ ), and negatively correlated with age in both genders (Fig 8). The 3 women with childhood onset of GH deficiency had higher median maintenance GH dose, 1.0 mg (0.83-1.33), then the 4 women with adulthood onset, 0.6 mg (0.33-1.0) ( $P=0.15$ ).




**Fig 8.** The GH-dose in relation to age.

Ekman B, Lindström T, Nyström F, Olsson AG, Toss G, Arnqvist HJ. A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults. *Eur J Endocrinol.* 2002 Jul;147(1):49-57.

# Timing och Könsskillnader



**Fig 5.** Mean IGF-I levels in 14 patients (7 males and 7 females) at baseline and after 2, 4 and 8 weeks on the startdose of 0.17 mg/day




**Fig 6.** Net increment of circulating IGF-I after 2 months on the start dose in relation to age. All 18 patients had a GH-dose of 0.17 mg/day.

Ekman B, Lindström T, Nyström F, Olsson AG, Toss G, Arnqvist HJ. A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults. *Eur J Endocrinol.* 2002 Jul;147(1):49-57.

# Effekter av titrerad GH substitution

- ▶ Ingen aktivering av RAAS
- ▶ LDL-Cholestrol sjunker 0,5 mmol/L
- ▶ Dynamisk muskelstyrka ökar kopplat till IGF-I ökning
- ▶ Fasteglukos och fasteinsulin ökar (normalisering?)
- ▶ Fritt T4 sjunker och fritt T3 ökar
- ▶ Benmassan minskar första året för att sedan öka



**Figure 10.** Plasma renin activity during GH-substitution and in control subjects. The boxes represent median and 25th to 75th percentiles. c=control subjects and p= patients.

Ekman B, Lindström T, Nyström F, Olsson AG, Toss G, Arnqvist HJ. A dose titration model for recombinant GH substitution aiming at normal plasma concentrations of IGF-I in hypopituitary adults. Eur J Endocrinol. 2002 Jul;147(1):49-57.



# Typ 1 diabetes och GH-IGF-I axeln




Fig 15. Mean plasma levels of IGF-I in patients with type 1 diabetes (black bars) compared to an age and sex matched reference population (white bars) Age distribution of controls/patients: 20-29 years n=41/28, 30-39 years n=42/54, 40-49 n=36/35 and 50-60 years n=44/17

Ekman B, Nyström F, Arnqvist HJ. Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. *Eur J Endocrinol.* 2000 Oct;143(4):505-10.

## The GH-IGF-I-insulin-system in insulin deficiency





Fig 18. Despite normal peripheral insulin concentrations by subcutaneous injections, the intraportal concentrations are much less in type 1 diabetes. This probably causes down regulation of the growth hormone receptor (GHR), and the corresponding growth hormone binding hormone (GHBP), and the stimulation of GH on IGF-I expression in the liver declines. The lowered levels of IGF-I induce increased levels of GH because of decreased negative feedback on the pituitary level. In addition IGFBP-1, which decreases the free fraction of IGF-I, is increased due to the portal hypo-insulinemia.

Thesis Bertil  
Ekman 2002

### IGFBP-1

(Unpublished data). IGFBP-1 was increased at baseline in the patients and decreased significantly after GH-substitution,  $P=0.014$ . The difference in baseline levels of IGFBP-1 was nearly significant between patients and controls  $P=0.051$ . Fasting insulin levels were negatively correlated with IGFBP-1 levels before GH-substitution  $r = -0.58$ ,  $P=0.016$ , an association which was weaker after GH-substitution,  $r = -0.45$ ,  $P=0.083$  (unpublished data)



**Fig 9.** IGFBP-1 levels before GH-substitution (T<sub>0</sub>) and at the end of the study (T<sub>end</sub>). ☆ indicates  $P < 0.05$  compared with baseline. Shaded bars = controls. White bars = patients.

Table 4. Multiple logistic regression of risk of developing diabetes. Odds ratios (OR, 95% CI) for developing diabetes mellitus postpartum at increasing levels of fasting blood glucose and 2-h OGTT blood glucose levels found at diagnosis of GDM.

Blood glucose at diagnosis (mmol/l)	Number of women at follow-up with		OR (95% CI)
	Diabetes	No diabetes	
<b>Fasting</b>			
≤4.5	42	263	1
4.6–5.0	51	188	1.7 (1.1–2.7)
5.1–5.5	49	160	1.9 (1.2–3.0)
5.6–6.0	40	78	3.2 (1.9–5.3)
≥6.1	79	56	8.8 (5.5–14)
<b>2 h OGTT</b>			
9.0–9.5	85	456	1
9.6–10.0	57	222	1.4 (0.95–2.0)
10.1–10.5	47	121	2.1 (1.4–3.1)
10.6–11.0	42	74	3.0 (2.0–4.8)
≥11.1	93	98	5.1 (3.5–7.3)

Wahlberg J, Ekman B, Nyström L, Hanson U, Persson B, Arnqvist HJ. Gestational diabetes: Glycaemic predictors for fetal macrosomia and maternal risk of future diabetes. *Diabetes Res Clin Pract.* 2016 Apr;114:99-105.

# Normal kortisol sekretion

- 8-15 mg/dygn
- 5.7 mg/m<sup>2</sup>/dygn ( 18 män i sen pubertet).  
Esteban et al JCEM 71 39-45, 1991.
- 5-7 mg/m<sup>2</sup>/dygn ( 5 män 7 kvinnor).  
Kerrigan et al JCEM 76, 1505-1510, 1993

Lite siffror (som får tas med en viss nypa salt)

Förbehållet att CBG-nivåer inte är förhöjda:

**”Under vilken kortisolnivå kan jag anse min misstanke vara bekräftad?”**

101 nmol/L med 98% säkerhet

65 nmol/L med 99% säkerhet

41 nmol/L med 100% säkerhet

**”Vid vilken nivå kan jag släppa misstanken?”**



340 nmol/L med 98% säkerhet

392 nmol/L med 99% säkerhet


400 nmol/L med 100% säkerhet

# Konventionell kortisonsubstitution till patienter med hypofysinsufficiens

Cortison acetat 25 mg +12.5 mg




Blomgren J, Ekman B, Andersson PO, Arnqvist HJ. Non-physiological levels of circulating cortisol in growth hormone-treated hypopituitary adults after conventional cortisone substitution. *Scand J Clin Lab Invest.* 2004 Apr;64(2):132-9.





**Fig. 1** Individual 24-h profiles of plasma ACTH (a) and plasma cortisol (b) and salivary cortisol (c) in 13 patients (8 females/5 males) with PAI treated with cortisone 12.5 mg cortisone acetate orally at 16:00h and 25 mg at 07:00h.



Ekman B, Blomgren J, Andersson PO, Carlsson M, Arnqvist HJ. Variable sensitivity to the glucocorticoid activity of cortisol in patients with primary adrenal insufficiency: assessment with ACTH profiles. *Horm Metab Res.* 2010 Dec;42(13):961-6.








Ekman B, Bachrach-Lindström M, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. *Clin Endocrinol (Oxf)*. 2012 Jul;77(1):18-25.




Ekman B, Bachrach-Lindström M, Lindström T, Wahlberg J, Blomgren J, Arnqvist HJ. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. *Clin Endocrinol (Oxf)*. 2012 Jul;77(1):18-25.

# Två eller 4 doser hydrokortison?




# Duocort



Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, Skrtic S. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. *J Clin Endocrinol Metab.* 2012 Feb;97(2):473-81.

# Duocort (Plenadren®)



Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM, Monson JP, Stewart PM, Lennernäs H, Skrtic S. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. *J Clin Endocrinol Metab.* 2012 Feb;97(2):473-81.

# Turnerakademin

Aortic dissection was the single largest cause of death in TS, accounting for 23% (8/35) of total deaths.

Thunström Sofia, Wide U, Landin-Wilhelmsen K, Berntorp K, Bryman I, Krantz E, Wahlberg J, Ekman B, Isakson M, Karlsson A, Bergström I, Naessén S. Psychiatric disorders and comorbidity in women with Turner Syndrome: a retrospective national cohort study. *Transl Psychiatry*. 2024 Sep 4;14(1):355.

There was no increase in psychiatric diagnosis within the group with time, nor correlation to specific karyotype or somatic comorbidity as congenital heart disease and hypothyroidism, hormonal treatment, or childbirth. In addition, the frequency of psychiatric diagnosis in TS was lower than in the population-based data.


Thunström Sofia, Wide U, Landin-Wilhelmsen K, Berntorp K, Bryman I, Krantz E, Wahlberg J, Ekman B, Isakson M, Karlsson A, Bergström I, Naessén S. Psychiatric disorders and comorbidity in women with Turner Syndrome: a retrospective national cohort study. *Transl Psychiatry*. 2024 Sep 4;14(1):355.

# EquiTest






# EquiTest



Vita staplar = Turner


Grå staplar = kontroller



Composite (a merge of all six recordings) was significantly lower in the TS-group,  $p < 0.05$ . In the TS group high total body weight was related to worse outcome on tests SO5, SO6, and composite, while total bone mass, age, height, or waist showed no significant association with balance scores. Our findings indicate that TS could have an increased risk for falling due to impaired ability to manage complex coordination tasks


Wahlberg J, Sydsjö G, Ledin T, Bågesund M, Ekman B. Impaired postural balance in turner syndrome. *Horm Metab Res.* 2013 Jul;45(7):537-40.

# Referens population/Turner S-Testosteron




20/1


**Figure 3** Testosterone concentrations (mean  $\pm$  95% CI) for all measured values in saliva (left) and serum and urine (right) in patients during intramuscular testosterone undecanoate injections every 12th week during 12 months and first and last injections.



Lood Y, Aardal-Eriksson E, Webe C, Ahlner J, Ekman B, Wahlberg J. Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism. *Andrology*. 2018 Jan;6(1):86-93.

**Figure 3** Hazard ratios (HRs) with 95% CIs for the outcome of overall death in patients with acromegaly until June 30, ...





**Figure 1. Catheter Placement for Bilateral Simultaneous Blood Sampling of the Inferior Petrosal Sinuses.**

Confluent pituitary veins empty laterally into the cavernous sinuses, which drain into the inferior petrosal sinuses.



# Sinus cavernosus kateterisering






Bild Sofia Melin



Jonas Robèrt et al  
 Cavernous Sinus Sampling in the Diagnosis of Endogenous Cushing Syndrome - a case series and methods description  
 Abstract ENEA, Sevilla sept 2024.




# Copeptin vid hypofyskirurgi




Jonas Rosander et al.  
Under databearbetning

# Akromegali



Arnardóttir S, Järås J, Burman P, Berinder K, Dahlqvist P, Erfurth EM, Höybye C, Larsson K, Ragnarsson O, Ekman B, Edén Engström B. Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. *Eur J Endocrinol.* 2022 Feb 1;186(3):329-339.

# Röstanalys vid akromegali



The machine learning model identified patients with acromegaly more accurately (area under the receiver operating curve [ROC AUC] 0.84) than experienced endocrinologists (ROC AUC 0.69).

Vouzouneraki K, Nylén F, Holmberg J, Olsson T, Berinder K, Höybye C, Petersson M, Bensing S, Åkerman AK, Borg H, Ekman B, Robért J, Engström BE, Ragnarsson O, Burman P, Dahlqvist P. Digital Voice Analysis as a Biomarker of Acromegaly. *J Clin Endocrinol Metab.* 2025 Mar 17;110(4):983-990.

# Svenska Hypofysregistret 2022-2024

1. Bengtsson D, Ragnarsson O, Berinder K, Dahlqvist P, Edén Engström B, Ekman B, Höybye C, Järås J, Valdemarsson S, Burman P, Wahlberg J. Increased Mortality Persists after Treatment of Cushing's Disease: A Matched Nationwide Cohort Study. *J Endocr Soc.* 2022 Mar 18;6(6):bvac045.
2. Petersson M, Berinder K, Edén Engström B, Tsatsaris E, Ekman B, Wahlberg J, Burman P, Borg H, Siesjö P, Dahlqvist P, Åkerman AK, Ragnarsson O, Olsson M, Förander P, Bensing S, Höybye C. Natural history and surgical outcome of Rathke's cleft cysts- A study from the Swedish Pituitary Registry. *ClinEndocrinol (Oxf).* 2022 Jan;96(1):54-61.
3. Al-Shamkhi N, Berinder K, Borg H, Burman P, Dahlqvist P, Höybye C, Olsson DS, Ragnarsson O, Ekman B, Edén Engström B. Pituitary function before and after surgery for nonfunctioning pituitary adenomas- data from the Swedish Pituitary Register. *Eur J Endocrinol.* 2023 Aug 2;189(2):217-224.
4. Himonakos C, Burman P, Borg H, Dahlqvist P, Engström BE, Ekman B, Emilsson L, Olsson DS, Ragnarsson O, Wahlberg J, Åkerman AK, Höybye C, Berinder K. Long-term Follow-up of 84 Patients With Giant Prolactinomas-A Swedish Nationwide Study. *J Clin Endocrinol Metab.* 2023 Nov 17;108(12):e1506-e1514.
5. Robèrt J, Tsatsaris E, Berinder K, Bonelli L, Burman P, Dahlqvist P, Höybye C, Olsson DS, Ragnarsson O, Vouzouneraki K, Åkerman AK, Ekman B, Edén Engström B. Establishing a valid cohort of patients with acromegaly by combining the National Patient Register with the Swedish Pituitary Register. *J Endocrinol Invest.* 2024 Apr;47(4):995-1003.

# Några saker att arbeta vidare med.

- **Teknik**

- Nya diagnostiska verktyg
- AI stödda insulinpumpar och sensorer. Billigare teknik borde komma så även typ 2 diabetes får sensorer som via smarta appar som inkluderar kombinerad livsvanestöd kan leda till bättre egenvård.

- ▶ **Förebygga sjukdomsuppkomst eller lindra sjukdomsförloppet**

- Screening för Typ 1 diabetes.
- Immunologisk behandling av typ 1 diabetes och potentiellt även för andra autoimmuna endokrina sjukdomar.
- Skall man medicinskt behandla primär aldosteronism med aldosteronreceptorblockad?
- Samarbete med andra specialiteter som använder behandling som allvarligt skadar hormonkörtlarna eller ger hormonella funktionsstörningar.

- ▶ **Förbättrad hormonbehandling**


- Strukturerad obesitasbehandling med mättnadshormoner. Samarbete med kirurgiska obesitascentrum
- Utveckla mera fysiologiska hormonbehandlingar. Hormonpumpar utöver insulinpumpar?

Linköping University Medical Dissertations

No. 757

# IGF-I in growth hormone deficiency and in type 1 diabetes

BERTIL EKMAN



Department of Medicine and Care, division of Internal Medicine  
Department of Biomedicine and Surgery, division of Cell Biology  
Linköpings universitet

Linköping 2002

Tack alla medarbetare  
från förr och framåt!